Costimulatory wars: The tumor menace

Arthur A. Hurwitz, Eugene D. Kwon, Andrea Van Elsas

Research output: Contribution to journalReview articlepeer-review

71 Scopus citations


Advances in our understanding of T cell costimulatory molecules have provided a vast array of novel approaches to tumor immunotherapy. In the past year, combinatorial immunotherapy based on earlier studies of CTLA-4 blockade, the identification of novel B7-family members, the modulation of CD40 to reverse tolerance to tumor-associated antigens and the use of OX40 to enhance antitumor responses of CD4+ T cells have all contributed to the development of more-powerful immunomodulatory cancer therapies. (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)589-596
Number of pages8
JournalCurrent Opinion in Immunology
Issue number5
StatePublished - 2000

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Costimulatory wars: The tumor menace'. Together they form a unique fingerprint.

Cite this